TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22709547

Group type: EXPERIMENTAL
Intervention: Intravenous-LPS 0.6 ng/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19357943

Group type: EXPERIMENTAL
Intervention: Messages from health care providers, group-level intervention, and peer-led support groups
Number of subjects: 184

Group type: COMPARATOR
Intervention: Brief messages from health care providers
Number of subjects: 184
Study: 17921791

Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel 1% applied 3 times a day for 30 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo gel applied 3 times a day for 30 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel 1%
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 74
Study: 15656699

Group type: EXPERIMENTAL
Intervention: Posaconazole 800 mg as a single dose (regimen A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg every 12 hours (regimen B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg every 6 hours (regimen C)
Number of subjects: 18
Study: 11854875

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 2 mg/kg/h for 4 hours or until rewarmed
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 10596305

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus isometric handgrip exercise
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus treadmill, symptom-limited exercise
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 240
Study: 7717820

Group type: EXPERIMENTAL
Intervention: Short-term exercise training for 3 months (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No exercise training (group B)
Number of subjects: 100
Study: 2201252

Group type: EXPERIMENTAL
Intervention: imipenem
Number of subjects: 89

Group type: COMPARATOR
Intervention: ceftazidime
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ceftazidime + cloxacillin/amikacin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: imipenem + cloxacillin/amikacin
Number of subjects: 89
Study: 6939000

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 0.25 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 0.50 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31606460

Group type: EXPERIMENTAL
Intervention: Pooled human immune globulin-eye drops (IVIG 4 mg/mL) twice a day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 0
Study: 31527581

Group type: EXPERIMENTAL
Intervention: Radiomics analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardization of radiomics process
Number of subjects: 0
Study: 28648412

Group type: EXPERIMENTAL
Intervention: Restrictive hydration with norepinephrine administration (1ml/kg/h initially, then 3ml/kg/h crystalloid infusion after cystectomy)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Liberal hydration (6ml/kg/h standard crystalloid infusion throughout surgery)
Number of subjects: 166
Study: 25564276

Group type: EXPERIMENTAL
Intervention: NexGard®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison between NexGard® and Bravecto™
Number of subjects: 24
Study: 24345529

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% once daily
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Nepafenac 0.1% three times daily
Number of subjects: 2016
Study: 21844132

Group type: COMPARATOR
Intervention: Imatinib alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Imatinib with turmeric powder
Number of subjects: 50
Study: 19605507

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg for patients receiving paclitaxel, 8 mg for those not receiving paclitaxel)
Number of subjects: 204
Study: 17589339

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 26
Study: 14671731

Group type: EXPERIMENTAL
Intervention: BDD patients
Number of subjects: 149
Study: 11516600

Group type: EXPERIMENTAL
Intervention: Dartmouth COOP Clinical Improvement System (DCCIS) and telephone-based nurse-educator intervention
Number of subjects: 703

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 703
Study: 9504319

Group type: EXPERIMENTAL
Intervention: Gastric restriction surgery
Number of subjects: 487

Group type: COMPARATOR
Intervention: Conventional weight reduction treatment
Number of subjects: 487
Study: 11271224

Group type: EXPERIMENTAL
Intervention: PUVA therapy (8‐methoxypsoralen and UVA irradiation)
Number of subjects: 75
Study: 3069135

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 1 microgram/min for up to 20 min
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (mean dosage of 18.5 ng/min/kg)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Panic attacks during isoproterenol infusions
Number of subjects: 131
Study: 30305114

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 10000
Study: 27824264

Group type: EXPERIMENTAL
Intervention: Luphere 3M Depot (leuprolide acetate dose of 11.25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lucrin Depot (leuprolide acetate dose of 11.25 mg)
Number of subjects: 20
Study: 26609031

Group type: EXPERIMENTAL
Intervention: Oral 25 mg dexketoprofen trometamol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Two puff lidocaine sprays on cervical mucosa
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 100 mg pethidine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous paracetamol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 144
Study: 24345424

Group type: EXPERIMENTAL
Intervention: Video decision aid with patient narratives
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Text decision aid with patient narratives
Number of subjects: 56

Group type: COMPARATOR
Intervention: Video decision aid without patient narratives (control)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Text decision aid without patient narratives (control)
Number of subjects: 56
Study: 16389004

Group type: EXPERIMENTAL
Intervention: Coached pushing
Number of subjects: 320

Group type: COMPARATOR
Intervention: Uncoached pushing
Number of subjects: 320
Study: 12594673

Group type: EXPERIMENTAL
Intervention: High-resolution MRI
Number of subjects: 98
Study: 10703393

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus 'low-dose' MMF (TMBIR)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Neoral plus 'low-dose' MMF (NMBIR)
Number of subjects: 53
Study: 8603630

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 73
Study: 1746006

Group type: EXPERIMENTAL
Intervention: Dipyridamole (400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (1 to 30 microM) with subthreshold concentration of NO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole with subthreshold concentration of PGI2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole with subthreshold concentration of NO and PGI2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7037035

Group type: EXPERIMENTAL
Intervention: Budesonide, 200 micrograms twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate, 100 micrograms four times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide and Beclomethasone dipropionate
Number of subjects: 30
Study: 31684921

Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy intervention including manual therapy, stretching, strengthening, and neuromuscular functional training.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home exercise program (HEP) designed for patients to perform without PT supervision.
Number of subjects: 0
Study: 28471713

Group type: EXPERIMENTAL
Intervention: Letter Advance Directive (LAD)
Number of subjects: 400
Study: 26059526

Group type: EXPERIMENTAL
Intervention: Desmopressin tablets for 6 months
Number of subjects: 744
Study: 22763199

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC): brochure, brief negotiated interview, 6 weeks of nicotine patches, and a telephone call
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual Care (UC): smoking cessation brochure
Number of subjects: 88
Study: 21720782

Group type: EXPERIMENTAL
Intervention: Positive Action intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19818720

Group type: EXPERIMENTAL
Intervention: Purified duck embryo vaccine (PDEV, Vaxirab)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell vaccine (PCEC, Rabipur)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Purified vero cell rabies vaccine (PVRV, Verorab)
Number of subjects: 152
Study: 16677223

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Brief therapy (BT)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Matched care approach (CAU)
Number of subjects: 702
Study: 15549275

Group type: EXPERIMENTAL
Intervention: Whole drink (containing 37.5 g glucose, 75 mg caffeine, ginseng and ginkgo biloba)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study: 11778791

Group type: EXPERIMENTAL
Intervention: Taifun (50 microg dose(-1) metered-dose dry powder inhaler)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Turbuhaler (50 microg dose(-1) dry powder inhaler)
Number of subjects: 21

Group type: COMPARATOR
Intervention: pMDI+S (100 microg dose(-1) pressurized metered-dose inhaler with a spacer)
Number of subjects: 21
Study: 8998204

Group type: EXPERIMENTAL
Intervention: Telephone-first method (telephone interviews with follow-up of nonrespondents by mail)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Mail-first method (mailed surveys with follow-up on nonrespondents by telephone)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Telephone-first method
Number of subjects: 252
Study: 8278215

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 47
Study: 3318428

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg taken at bedtime
Number of subjects: 264

Group type: COMPARATOR
Intervention: Aspirin 900 mg four times daily
Number of subjects: 264
Study: 29384571

Group type: EXPERIMENTAL
Intervention: Interprofessional Education (IPE) activity with nonhealth care students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26662031

Group type: EXPERIMENTAL
Intervention: Ultra‐rapid opioid detoxification (UROD) combined with naltrexone treatment (NMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 14
Study: 25311370

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program with telephone coaching (8-week program)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control arm (no access to the website, weekly telephone call as attention-strategy)
Number of subjects: 29
Study: 23900058

Group type: EXPERIMENTAL
Intervention: Oral supplementation of a bacterial lysate between week 5 and the end of month 7 (intervention group)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 571
Study: 19761514

Group type: EXPERIMENTAL
Intervention: Massage therapy (15 min daily, 5 days/week for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham treatment (light still touch, same duration as intervention)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24
Study: 18851788

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Late course accelerated hyperfractionated radiotherapy (LCAF)
Number of subjects: 44
Study: 16627810

Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 2359

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2359

Group type: EXPERIMENTAL
Intervention: Combined assessment of troponin-T and sCD40L
Number of subjects: 2359
Study: 14616460

Group type: EXPERIMENTAL
Intervention: Watching the cystoscopy on closed‐circuit television with an explanation during the procedure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Explanations alone
Number of subjects: 51
Study: 10993781

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no vitamin C)
Number of subjects: 48
Study: 8638548

Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil (5FU) 400 mg/m2, days 1‐5 and folinic acid (FA) 200 mg/m2, days 1‐5
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil (5FU) 400 mg/m2, days 1‐5 and folinic acid (FA) 200 mg/m2, days 1‐5 with ifosfamide (IFO) 5 g/m2, day 1 and Mesna
Number of subjects: 55
Study: 1294028

Group type: EXPERIMENTAL
Intervention: Early instillation of mitomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall early instillation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late instillation of mitomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early instillation of adriamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late instillation of adriamycin
Number of subjects: 0
Study: 6492907

Group type: EXPERIMENTAL
Intervention: Surrogate Sickness Impact Profile (SIP) score
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Surrogate SIP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Surrogate SIP total and dimension scores
Number of subjects: 66
Study: 30620771

Group type: COMPARATOR
Intervention: Hypothetical community-based health insurance (CBHI) schemes with various benefit package components including insurance coverage for medical consultations, hospitalizations, traffic accidents, pharmaceuticals, transportation, premiums, and prepaid discounts.
Number of subjects: 5800
Study: 29401325

Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (30 µg nonadjuvanted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (60 µg nonadjuvanted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (60 µg aluminum-adjuvanted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tdap vaccine (control)
Number of subjects: 0
Study: 26920602

Group type: EXPERIMENTAL
Intervention: Continued novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interrupted novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued novel oral anticoagulant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interrupted novel oral anticoagulant
Number of subjects: 0
Study: 24457590

Group type: EXPERIMENTAL
Intervention: Escitalopram (N=47)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST; 12 total sessions, N=53)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (N=49)
Number of subjects: 149
Study: 22169268

Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy (n=942)
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Radical prostate radiotherapy (n=637)
Number of subjects: 1613
Study: 20969657

Group type: EXPERIMENTAL
Intervention: Cohesive polydensified matrix hyaluronic acid (CPMHA)
Number of subjects: 95
Study: 17197012

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAVH/BSO)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Postoperative adjuvant whole pelvic radiation therapy (WPRT)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Intravaginal radiation therapy (IVRT)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Total direct medical costs
Number of subjects: 1312
Study: 15781667

Group type: EXPERIMENTAL
Intervention: High selenium level (4th versus 1st quartile) among men with AA genotype
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: High selenium level among men with VV/VA genotype
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Beta-carotene treatment among men with AA genotype
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: Combination of antioxidants (selenium, lycopene, alpha-tocopherol) among men with AA genotype
Number of subjects: 1331
Study: 12110034

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Post one year (all groups receiving rhGH)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 10422040

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen 0.625 mg daily plus progestogen (norgestrel) 150 micrograms for the last 12 days of each 28 day cycle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day for 28 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 38
Study: 7758644

Group type: EXPERIMENTAL
Intervention: Tampon A
Number of subjects: 41
Study: 2083474

Group type: EXPERIMENTAL
Intervention: Commercial prebrushing rinse (Plax)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 16
Study: 343738

Group type: EXPERIMENTAL
Intervention: Propranolol administered 1 to 2 hours prior to operation (Group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Propranolol discontinued 48 hours prior to operation (Group 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 27
Study: 29443404

Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula (IF) 400 mL/d for 10 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Commonly used formula (CF)
Number of subjects: 38
Study: 26963897

Group type: EXPERIMENTAL
Intervention: DHEA 25 mg three times daily for 12 weeks before IVF/ICSI cycles
Number of subjects: 140
Study: 24793931

Group type: EXPERIMENTAL
Intervention: Written preoperative information (Group W)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Verbal preoperative information (Group V)
Number of subjects: 190
Study: 23810122

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 40
Study: 19913254

Group type: EXPERIMENTAL
Intervention: Cystoscopy with knowledge of positive urine test results (226 patients)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cystoscopy without knowledge of positive urine test results (120 cystoscopies)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Cystoscopy with negative urine test results (260 patients in intervention arm)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cystoscopy with negative urine test results (326 patients in control arm)
Number of subjects: 448
Study: 18165149

Group type: EXPERIMENTAL
Intervention: Facilitatory TBS of the affected motor cortex
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhibitory TBS of the unaffected motor cortex
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 12
Study: 17260879

Group type: EXPERIMENTAL
Intervention: Benzodiazepine drugs (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Benzodiazepine and GABAergic drugs (group 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 30
Study: 11682404

Group type: EXPERIMENTAL
Intervention: Large-dose oral buspirone (60 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Large-dose IV meperidine (target plasma concentration of 0.8 microg/mL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of buspirone (30 mg) and meperidine (0.4 microg/mL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 8
Study: 9728378

Group type: EXPERIMENTAL
Intervention: Functional restoration program (n = 621)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Control outpatient programs (n = 144)
Number of subjects: 816

Group type: COMPARATOR
Intervention: No treatment (n = 51)
Number of subjects: 816
Study: 8069895

Group type: EXPERIMENTAL
Intervention: MCT OIL (15 ml daily providing 545 kJ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Strict reducing diet without oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MCT OIL
Number of subjects: 60
Study: 3192038

Group type: EXPERIMENTAL
Intervention: 40‐g low‐protein diet (LPD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: usual‐protein diet (UPD)
Number of subjects: 10
Study: 1592958

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 354471

Group type: EXPERIMENTAL
Intervention: Carbenoxolone 50 mg three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31904342

Group type: EXPERIMENTAL
Intervention: Multidisciplinary 12-week exercise-based cardiac rehabilitation program
Number of subjects: 607
Study: 31556637

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive tone of voice
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Controlling tone of voice
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Neutral tone of voice
Number of subjects: 1000
Study: 27277518

Group type: EXPERIMENTAL
Intervention: Zirconia primary crowns
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cobalt-chromium alloy primary crowns
Number of subjects: 56